STAT

For rules on creating ‘CRISPR babies’ from edited embryos, scientists call a do-over

Guidelines from 2017 on CRISPR'ing human embryos didn't stop He Jiankui from creating "CRISPR babies." Now a commission is redrafting the rules.

The second-most shocking thing He Jiankui told the international genome editing summit in Hong Kong last November — right after announcing that twin girls had been born from embryos whose DNA he’d changed with CRISPR — was that he’d followed guidelines on embryo editing set forth by a panel of leading U.S. scientists and ethicists.

That committee of the National Academies of Science, Engineering, and Medicine basically said, in 2017: If society agrees this is OK, proceed with extreme caution. He claimed he had checked all the panel’s boxes, meeting a long list of criteria that include editing only genes “convincingly demonstrated” to cause the disease, conducting “credible” animal studies first, and having “reliable oversight mechanisms.”

Whether he

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks